Skip to main content
. 2021 Jul 28;12:697840. doi: 10.3389/fimmu.2021.697840

Figure 3.

Figure 3

CD14+ CD169+ monocytes are present in cancer patients. (A) Analysis of public scRNA-seq dataset of PBMCs from PDAC patients (n = 12) and healthy controls (n = 4) using Seurat algorithm and projected onto UMAP space where cell types are indicated. The expressions of CD14 and SIGLEC1 are visualized on UMAP. (B) Analysis of public scRNA-seq dataset of PBMCs from patients with lung cancer (n = 7) using Seurat and UMAP clustering. The expression of SIGLEC1 and CD14 are shown. (C) Percentage of CD169+ cells within classical (CD14+ CD16-), intermediate (CD14+ CD16+), or non-classical (CD14- CD16+) monocytes in patients with pancreatic ductal adenocarcinoma (PDAC, n = 4), hepatocellular carcinoma (HCC n = 7), colorectal liver metastasis (CRLM, n = 4), and melanoma (n = 4). Monocytes were gated on live, HLA-DR+ Lin(CD3/CD19/CD56)– cells. (D) Expression of HLA-DR between CD169+ and CD169- classical or intermediate monocytes in cancer patients. Paired t-tests were used. ****P < 0.0001.